We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
Read MoreHide Full Article
The latest trading session saw Medpace (MEDP - Free Report) ending at $330.59, denoting a +1.96% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of 1.77%. Meanwhile, the Dow gained 1.42%, and the Nasdaq, a tech-heavy index, added 2.28%.
Coming into today, shares of the provider of outsourced clinical development services had lost 4.7% in the past month. In that same time, the Medical sector lost 1.17%, while the S&P 500 lost 5.73%.
Analysts and investors alike will be keeping a close eye on the performance of Medpace in its upcoming earnings disclosure. The company's earnings report is set to go public on April 21, 2025. It is anticipated that the company will report an EPS of $3.05, marking a 4.69% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $532.52 million, reflecting a 4.2% rise from the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $12.29 per share and a revenue of $2.16 billion, indicating changes of -2.69% and +2.41%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Medpace. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Medpace is currently a Zacks Rank #3 (Hold).
Digging into valuation, Medpace currently has a Forward P/E ratio of 26.38. This valuation marks a premium compared to its industry's average Forward P/E of 15.87.
Meanwhile, MEDP's PEG ratio is currently 3.58. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical Services industry had an average PEG ratio of 1.44 as trading concluded yesterday.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Medpace (MEDP) Outperforms Broader Market: What You Need to Know
The latest trading session saw Medpace (MEDP - Free Report) ending at $330.59, denoting a +1.96% adjustment from its last day's close. The stock outperformed the S&P 500, which registered a daily gain of 1.77%. Meanwhile, the Dow gained 1.42%, and the Nasdaq, a tech-heavy index, added 2.28%.
Coming into today, shares of the provider of outsourced clinical development services had lost 4.7% in the past month. In that same time, the Medical sector lost 1.17%, while the S&P 500 lost 5.73%.
Analysts and investors alike will be keeping a close eye on the performance of Medpace in its upcoming earnings disclosure. The company's earnings report is set to go public on April 21, 2025. It is anticipated that the company will report an EPS of $3.05, marking a 4.69% fall compared to the same quarter of the previous year. At the same time, our most recent consensus estimate is projecting a revenue of $532.52 million, reflecting a 4.2% rise from the equivalent quarter last year.
In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $12.29 per share and a revenue of $2.16 billion, indicating changes of -2.69% and +2.41%, respectively, from the former year.
Investors should also take note of any recent adjustments to analyst estimates for Medpace. These revisions help to show the ever-changing nature of near-term business trends. As a result, we can interpret positive estimate revisions as a good sign for the company's business outlook.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To exploit this, we've formed the Zacks Rank, a quantitative model that includes these estimate changes and presents a viable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the last 30 days, the Zacks Consensus EPS estimate has remained unchanged. Medpace is currently a Zacks Rank #3 (Hold).
Digging into valuation, Medpace currently has a Forward P/E ratio of 26.38. This valuation marks a premium compared to its industry's average Forward P/E of 15.87.
Meanwhile, MEDP's PEG ratio is currently 3.58. This metric is used similarly to the famous P/E ratio, but the PEG ratio also takes into account the stock's expected earnings growth rate. The Medical Services industry had an average PEG ratio of 1.44 as trading concluded yesterday.
The Medical Services industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 77, which puts it in the top 31% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Be sure to use Zacks.com to monitor all these stock-influencing metrics, and more, throughout the forthcoming trading sessions.